Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis - Wikidata - awgldk - TriplyDB

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

http://www.wikidata.org/entity/Q35031351

about

Current strategies to treat tuberculosis Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease Complexation of clofazimine by macrocyclic cucurbit[7]uril reduced its cardiotoxicity without affecting the antimycobacterial efficacy.Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with Mycobacterium tuberculosis following Isoniazid Therapy.Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.A far-red fluorescent probe for flow cytometry and image-based functional studies of xenobiotic sequestering macrophages Evidence for the presence of clofazimine and its distribution in the healthy mouse brain.Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis Chemical Analysis of Drug Biocrystals: A Role for Counterion Transport Pathways in Intracellular Drug Disposition.Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.Clofazimine Biocrystal Accumulation in Macrophages Upregulates Interleukin 1 Receptor Antagonist Production To Induce a Systemic Anti-Inflammatory State Turning the respiratory flexibility of Mycobacterium tuberculosis against itself.Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.The paradigm shift to end tuberculosis. Are we ready to assume the changes?Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.Targeting Phenotypically Tolerant Mycobacterium tuberculosis.Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery.Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro.Old Antibiotics for Tuberculosis.Subcellular Partitioning and Intramacrophage Selectivity of Antimicrobial Compounds against Mycobacterium tuberculosis.Blockade of the Kv1.3 K+ Channel Enhances BCG Vaccine Efficacy by Expanding Central Memory T Lymphocytes.Reply to Levis and Rendini.Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children.Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.Macrophage-Mediated Clofazimine Sequestration Is Accompanied by a Shift in Host Energy Metabolism.Clofazimine Mechanisms of Action in Mycobacteria, HIV, and Cancer.Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.Therapy for Infection: Beyond 2018 Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

P2860

Q28075252-0599654D-FACE-49A9-ADFC-F10F6956A05B Q28552524-5F8D2538-ED36-48D5-B31C-637B28EAB4D6 Q31116166-296FF55C-C562-49A0-9F80-05F8B25D7899 Q33589762-CDB9B2F5-83EB-4E43-A00A-E5402B243A71 Q33854476-C40522A3-2315-40B8-B973-51DC9C34FF5D Q35607808-2F63BEF7-EA90-4164-9F6B-223CB2E09EEE Q35673729-8391D9F4-1771-468E-A6A0-2F2E515773C8 Q35712475-38903FF4-90BC-4B8C-A915-80203BA9BC3F Q35859964-188CDD18-C471-4AF4-9589-3B6EAEBE72D8 Q35962789-9CB49183-6B1D-4E1A-B271-8295D7F057F8 Q36057273-BF128354-5D5F-4B7E-8A9F-0E63B27566C6 Q36821344-74B3EC7C-32E2-481E-BC84-D445D3FDAA1A Q36888058-53F5F460-AAC6-4B11-BBA2-AC89C5A25C1E Q36933396-ECF38471-CF7C-4811-BB7A-D8C2B24D528B Q37181195-FAD3D26E-69F4-4529-A5AE-DB4BB9E48F4F Q37619123-2D4FAACA-9440-4A5E-A1A6-A90518C04011 Q38404398-DBFFE153-1815-4B99-9224-60590726F31C Q38652464-9D864B14-F3B3-470C-A048-19767133F2CF Q38676708-32515A2C-3AA5-41BA-AE81-403BCCF46CBD Q38838051-15D48242-B46B-404C-9165-78EE7A78E5A5 Q38995175-AC74AB0F-C1C0-48EE-B728-5F7646A3ACB3 Q39149038-6896BFAA-B6C4-476A-B063-DA31B57702E1 Q39231486-132C5CF7-A816-417F-8A1A-BB986DDBFB6B Q39235946-BAB2F422-913E-42F7-B707-1BA71AF53315 Q40237873-6706BA60-B7D1-49B0-BF08-1D0214D6FD54 Q40270392-316E5543-CB3B-47F0-B682-88A0AC792545 Q40385508-87FF4F31-98A7-4AB7-9E04-C6D7CC171E7A Q40559656-0AAE476C-FB0C-46C0-9342-50F4B1996E91 Q42234222-4BB6922B-030C-4622-A8EC-4946EDE4C36B Q45198957-37D1B110-9F7B-4BE3-BFB0-1F28E4B84020 Q47244908-902EC3F8-A0D1-4DD0-A97A-0706A9A2D3E0 Q50780166-0D98174A-4506-4915-86D7-00EB30FFE84D Q52677571-4064432B-EA7C-4429-B7B0-71B5BECB3D3A Q53504362-8909CF9F-3B1A-4D35-83B2-D18225B4EE64 Q53686602-08E3D4EC-6117-413E-A2CA-4A9448E37CA0 Q55268364-81AADA0D-68C4-44E0-9464-3501DFA005E2 Q57492415-BB1F237E-D9F2-4239-A19A-89093152A3F8 Q58785246-EA7D940E-07BA-46C7-A63D-48BA4DFDE0D0

P2860

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

http://www.wikidata.org/entity/Q35031351

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Clofazimine shortens the durat ...... l chemotherapy of tuberculosis

@ast

Clofazimine shortens the durat ...... l chemotherapy of tuberculosis

@en

type

label

Clofazimine shortens the durat ...... l chemotherapy of tuberculosis

@ast

Clofazimine shortens the durat ...... l chemotherapy of tuberculosis

@en

prefLabel

Clofazimine shortens the durat ...... l chemotherapy of tuberculosis

@ast

Clofazimine shortens the durat ...... l chemotherapy of tuberculosis

@en

P1433

Q35031351-215182F6-BFAC-45FE-9ABE-DCE4AC1A3EB8

P1476

Q35031351-DF9B619C-6A20-4D1C-84A8-82F297C5D2BF

P2093

Q35031351-1B8362A3-1D8B-4A7E-B3E4-0BA4274D9B8B

Q35031351-1E13D9CF-7E9E-433C-93FB-4CACD4FB8E88

Q35031351-4C1189FE-98D0-4256-9A74-EEE576C33272

Q35031351-7932F1E4-4417-4BDF-B65C-BA6C6343FE16

Q35031351-B0F1C1F1-B040-496F-B407-51F285E304E3

Q35031351-CE727211-DF0B-4B03-83CB-6FBD21BFA910

P2860

Q35031351-18F5EB12-B524-4A72-99E3-8BF28D543E38

Q35031351-190577CE-7357-46FE-8A25-DE2759D5879E

Q35031351-371C1FAB-30C5-4D51-A1C0-623D661A9132

Q35031351-3A109A33-D0E5-4E97-B663-8F63607BB6F9

Q35031351-41FD73F2-0848-4761-A81C-52707AF3C78E

Q35031351-4433058C-8FA0-4B51-A309-BFD0A99EAFFE

Q35031351-47B011A8-B043-48EA-B63F-C8339ACCAAFF

Q35031351-59995CDC-827D-4ABD-A5F1-F8ED9F4F53F6

Q35031351-60269395-375B-48FB-9A16-EDDE8FEBDFE3

Q35031351-61D1EF73-CF2C-4439-8401-E2808618035E

P304

Q35031351-6D5B19EF-4B9A-45C3-885C-4F4FF4235BF4

P31

Q35031351-DC87B8CE-9779-40D9-A652-04BB541F480C

P356

Q35031351-61E4C0FE-491D-4A1B-AE33-9723ABA4C122

P407

Q35031351-E26027FC-DF32-4827-852A-D88351CEDE40

P433

Q35031351-A468F5B0-F78B-4B16-850F-F34442C56278

P478

Q35031351-3DC7F8DB-029B-418A-BD65-4726CCC265E8

P50

Q35031351-7C0F8C65-B0E0-47ED-8687-1683BFE4DA93

Q35031351-FDB67CFC-C0E6-4263-94E7-853A6080031A

P577

Q35031351-37F8A28F-037B-4505-BD7F-C9C4252A9C6E

P5875

Q35031351-EBA29E64-516C-4D99-8492-046AC159629D

P698

Q35031351-CA95EA50-4B06-45A1-BA8C-1F64F15BE395

P921

Q35031351-789798AA-BF37-4FAA-A855-947ACF6A972E

Q35031351-8D5F9903-3BB6-447B-9DB1-D3C27EB83FA3

P932

Q35031351-7AAE8F78-DF19-4E99-9A3C-5598D6EDF0D8

P356

PNAS.1416951112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Clofazimine shortens the durat ...... l chemotherapy of tuberculosis

@en

P2093

Deepak V Almeida

http://www.w3.org/2001/XMLSchema#string

Jacques H Grosset

http://www.w3.org/2001/XMLSchema#string

John Adamson

http://www.w3.org/2001/XMLSchema#string

Paul J Converse

http://www.w3.org/2001/XMLSchema#string

Sandeep Tyagi

http://www.w3.org/2001/XMLSchema#string

Si-Yang Li

http://www.w3.org/2001/XMLSchema#string

P2860

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system

Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas

Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice

Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions

Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.

Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings.

P304

869-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1416951112

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Nicole C Ammerman

Rosemary V Swanson

P577

2015-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273186694

http://www.w3.org/2001/XMLSchema#string

P698

25561537

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

4311815

http://www.w3.org/2001/XMLSchema#string